| October 18, 2019 |
Amgen Comments on ICER’s Proposed Changes to the 2020 Value Assessment Framework
|
| September 9, 2019 |
Amgen Comments on ICER’s Proposed Methods Adaptations For Assessments of Potential Cures and Other Transformative Therapies
|
| September 4, 2019 |
Amgen Response in Support of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
|
| July 11, 2019 |
Amgen Comments on PCSK9 Patent Litigation in Germany
|
| June 17, 2019 |
Amgen Comments for ICER’s 2020 Value Assessment Framework
|
| June 14, 2019 |
Helping Patients Understand the Price of Their Medicines
|
| May 2, 2019 |
Amgen Reaches Settlement With Coherus in Trade Secrets Case Regarding Pegfilgrastim
|
| April 25, 2019 |
Amgen Reaches Settlement Agreement To Resolve Allegations Related To Patient Assistance Programs
|
| February 21, 2019 |
Amgen’s Comments on ICER’s Value-Based Price Of A Cure Collaborative: Methodological Considerations
|
| February 13, 2019 |
Amgen’s Comments on ICER’s Price Increase Draft Protocol
|
| November 14, 2018 |
Amgen Response in Support of the 2018 AHA/ACC Cholesterol Clinical Practice Guidelines
|
| July 27, 2018 |
Amgen Statement on Pricing |
| May 31, 2018 |
Amgen Statement on Complete Response Letter from the U.S. FDA for ABP 980, a Biosimilar Candidate to Herceptin® (Trastuzumab) |
| May 8, 2018 |
Amgen Response to ICER’s Draft Evidence Report and Voting Questions on CGRP Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine |
| March 7, 2018 |
Amgen’s Final Summary Comments on ICER’s CAR-T Assessment
|
| January 19, 2017 |
Amgen Response to ICER’s Draft Evidence Report and Voting Questions on CAR-T Therapy for B-Cell Cancers
|
| December 21, 2017 |
Amgen’s Response to ICER’s Draft Scoping Document on Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value (Condition Update)
|
| December 20, 2017 |
Amgen Response to ICER’s Draft Scoping Document on
CGRP Preventive Therapy for Migraine
|
| November 30, 2017 |
Amgen’s Statement on Cost Effectiveness of KYPROLIS® (carfilzomib) Compared to Velcade® (bortezomib) in Relapsed or Refractory Multiple Myeloma, Published in Expert Review of Hematology
|
| October 26, 2017 |
Amgen Statement on the Economic Benefit of XGEVA® (denosumab) Versus Zoledronic Acid in the Prevention of Bone Complications in Multiple Myeloma
|
| October 25, 2017 |
Amgen Provides Update on Status of Puerto Rico Operations
|
| October 6, 2017 |
Amgen Provides Update on Status of Puerto Rico Operations
|
| October 5, 2017 |
Amgen Statement on Appeals Court Decision on PCSK9 Antibody Patents
|
| September 25, 2017 |
Amgen Response to ICER’s Proposed Adaptation of the
ICER Value Framework for the Assessment of Treatments for Ultra-Rare Conditions
|
| August 31, 2017 |
Amgen Response to ICER’s Draft Scoping Document on CAR-T Therapy for B-Cell Cancers
|
| June 30, 2017 |
Amgen’s Position on Orphan Drugs and ICER’s Orphan Drug Assessment
|
| June 2, 2017 |
Amgen’s Response to the Institute for Clinical and Economic Review (ICER) Draft Report on Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value
|
| May 5, 2017 |
Amgen Response to ICER's Updated Value Assessment Framework - Recommendations for Value Assessment of PCSK9 Inhibitors
|
| April 27, 2017 |
Amgen Statement and Response to ICER Revised Value Framework Proposal and Osteoporosis Revised Scoping Document
|
| April 23, 2017 |
Amgen Response to Washington State Health Technology Assessment (HTA) Program's Draft Evidence Report on the Treatment of Chronic Migraines and Chronic Tension-type Headache
|
| April 3, 2017 |
Amgen’s Response to ICER’s Call for Comments on its “Updated” Value Framework - Executive Summary
|
| February 16, 2017 |
Amgen Statement and Response to ICER Rheumatoid Arthritis Draft Evidence Report
|
| December 28, 2016
|
Amgen Introduces New Value-Based Pharmacy Benefits Insurance Provision for U.S. Staff Members |
| October 20, 2016 |
Amgen Response to ICER Plaque Psoriasis Draft Evidence Report |
| September 12, 2016 |
Amgen Response to ICER’s Call for Comments on its Value Assessment Framework |
| September 9, 2016 |
Amgen Statement on the Clinical and Economic Value of BLINCYTO® (Blinatumomab) in Treating Adults With Relapsed or Refractory Philadelphia Chromosome Negative B-Cell Precursor Acute Lymphoblastic Leukemia |
| August 19, 2016 |
Amgen’s Response to ICER’s Background and Draft Scoping Document: “Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis: Effectiveness and Value” |
| August 16, 2016 |
Amgen Statement Regarding PCSK9 Economic Analysis Published in JAMA: "Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease" |
| July 26, 2016 |
Amgen Response to the Proposed ICER Review of Treatments for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) "Open Input" |
| April 8, 2016 |
Amgen's Response to ICER's Draft Report ‘Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness and Value’
|
| July 1, 2016 |
Amgen’s Response to ICER’s Background and Draft Scoping Document: “Treatment Options for Plaque Psoriasis: Effectiveness, Value, and Value-Based Price Benchmarks”
|
| March 31, 2016 |
Amgen's Response to Technology Assessments for Kyprolis® (Carfilzomib) in Multiple Myeloma
|
| September 28, 2015 |
Amgen Response to The Institute for Clinical and Economic Review (ICER) Draft Report on Effectiveness, Value, and Pricing Benchmarks for PCSK9 Inhibitors for High Cholesterol
Additional Background
Draft report released by ICER for public comment:
http://cepac.icer-review.org/wp-content/uploads/2015/04/PCSK9_Draft_Report_0908152.pdf
Comments from the National Pharmaceutical Council in response to the ICER Value Framework: http://www.icer-review.org/wp-content/uploads/2014/01/NPC-ICER-Framework-Slides.pdf |
| August 6, 2014 |
Amgen Response to USA Today Article on Restructuring
|
| May 8, 2014 |
Amgen Statement on EMA Review of Ivabradine |
| April 16, 2014 |
Amgen Statement on FDA Fast Track Designation for Investigational Ivabradine |
| April 3, 2014 |
Commercialize Prolia on Its Own in the European Union Switzerland Norway Russia and Mexico |
| March 7, 2014 |
Amgen Statement on Evolocumab Proactive Monitoring |
| February 11, 2014 |
Amgen Statement on Jan. 27, 2014, FDA Warning Letter |
| February 4, 2014 |
Amgen Statement on Support for Sound Science-Based Biosimilar Policies |
| December 20, 2013 |
Amgen Submits Comments to FDA on Biosimilars Naming Citizen Petitions |
| December 6, 2013 |
Amgen Supports Distinguishable Naming Policy for Biosimilars |
| October 12, 2013 |
Amgen Statement on Veto for California Biosimilars Bill |
| September 20, 2013 |
Amgen Statement on GPhA Citizen Petition on Naming for Biologics |
| November 21, 2013 |
Amgen Statement on Analyst Comments Concerning Kyprolis Trial Data |
| June 24, 2013 |
Amgen Response to The New England Journal of Medicine Study |
| June 11, 2013 |
Neulasta and the 340B Drug Discount Program
|
| April 22, 2013 |
Amgen Welcomes European Commission Report on EU Biosimilars Uptake |
| April 17, 2013 |
Amgen Statement on Additional Biomarker Analysis Beyond KRAS From Completed Phase 3 Study |
| April 8, 2013 |
Response to the Editorial "Building a wall against biosimilars" April 2013 Issue of Nature Biotechnology |
| March 24, 2013 |
Amgen Supports World Health Organizations Proposed Distinguishable Naming Policy for Biosimilars |
| February 22, 2013 |
Amgen Statement on Government Budget Analysis for Oral-Only Treatments for Dialysis Patients |
| February 1, 2013 |
Amgen Response to Recent New York Times Story "Biotech Firms, Billions at Risk, Lobby States to Limit Generics" |
| January 29, 2013 |
Amgen Response to Recent New York Times Stories and an Editorial That Are Based on Misunderstanding of the Facts |
| January 16, 2013 |
Amgen Statement on Stroke Research |